0001209191-17-059626.txt : 20171107
0001209191-17-059626.hdr.sgml : 20171107
20171107170649
ACCESSION NUMBER: 0001209191-17-059626
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20171107
FILED AS OF DATE: 20171107
DATE AS OF CHANGE: 20171107
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: GEMAYEL GEORGES
CENTRAL INDEX KEY: 0001256088
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37601
FILM NUMBER: 171184288
MAIL ADDRESS:
STREET 1: 550 HILLS DRIVE
CITY: BEDMINSTER
STATE: NJ
ZIP: 07921
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Dimension Therapeutics, Inc.
CENTRAL INDEX KEY: 0001592288
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 463942159
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 840 MEMORIAL DRIVE
STREET 2: 4TH FLOOR
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
BUSINESS PHONE: 617-401-0011
MAIL ADDRESS:
STREET 1: 840 MEMORIAL DRIVE
STREET 2: 4TH FLOOR
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2017-11-07
1
0001592288
Dimension Therapeutics, Inc.
DMTX
0001256088
GEMAYEL GEORGES
C/O DIMENSION THERAPEUTICS, INC.
840 MEMORIAL DRIVE, 4TH FLOOR
CAMBRIDGE
MA
02139
1
0
0
0
Stock Option (Right to Buy)
4.85
2017-11-07
4
D
0
44474
D
2025-08-11
Common Stock
44474
0
D
Stock Option (Right to Buy)
7.08
2017-11-07
4
D
0
32069
D
2026-05-18
Common Stock
32069
0
D
Stock Option (Right to Buy)
1.15
2017-11-07
4
D
0
17000
D
2027-05-24
Common Stock
17000
0
D
This stock option, which vests in equal monthly installments over 48 months beginning July 15, 2015, was assumed by Ultragenyx Pharmaceutical Inc. ("Ultragenyx"), and converted in accordance with the exchange ratio as set forth in the Agreement and Plan of Merger (the "Merger Agreement"), dated October 2, 2017, between the Issuer, Ultragenyx and Mystic River Merger Sub Inc., a direct, wholly-owned subsidiary of Ultragenyx.
These options were assumed by Ultragenyx and converted in accordance with the exchange ratio as set forth in the Merger Agreement.
These options, which vest in full on the earlier of May 25, 2018 or the Issuer's next annual meeting of stockholders, subject to the director's continued service on the Board, were assumed by Ultragenyx and converted in accordance with the exchange ratio as set forth in the Merger Agreement.
/s/ Mary Thistle, as Attorney-in-Fact for Georges Gemayel
2017-11-07